Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
Pfizer reported Q2 2026 revenue of $15.0 billion, representing 1% operational growth, and raised its full-year 2026 revenue guidance by $500 million at the midpoint to a range of $60.5 billion to $62.5 billion. Excluding COVID-19 products, revenue grew 5% operationally, while the company's core launched and acquired products portfolio delivered strong 18% operational growth driven by Eliquis, Padcev, and the Vyndaqel family. Adjusted diluted EPS was $0.77, flat with the prior year, while reported results reflected a non-cash intangible asset impairment charge of $4.3 billion resulting in a loss per share of $(0.04).
Key figures
- Eps
- 0.77
- Revenue
- $15.034 billion
- Guidance
- FY26 revenue $60.5B-$62.5B; Adjusted EPS $2.80-$3.00
- Revenue Yoy
- 1%
- Dividend per share
- $0.86
- Impairment charges
- $4.3 billion
- Non covid operational growth
- 5%
- Productivity savings 2027 2029
- $2.5 billion
- Remaining buyback authorization
- $3.3 billion
- Launched products operational growth
- 18%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.